JP2025501731A5 - - Google Patents
Info
- Publication number
- JP2025501731A5 JP2025501731A5 JP2024536420A JP2024536420A JP2025501731A5 JP 2025501731 A5 JP2025501731 A5 JP 2025501731A5 JP 2024536420 A JP2024536420 A JP 2024536420A JP 2024536420 A JP2024536420 A JP 2024536420A JP 2025501731 A5 JP2025501731 A5 JP 2025501731A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- optionally substituted
- therapeutic
- lnp
- lnp preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163291639P | 2021-12-20 | 2021-12-20 | |
| US63/291,639 | 2021-12-20 | ||
| US202263354627P | 2022-06-22 | 2022-06-22 | |
| US63/354,627 | 2022-06-22 | ||
| PCT/US2022/053209 WO2023121975A1 (en) | 2021-12-20 | 2022-12-16 | Ionizable amine lipids and lipid nanoparticles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501731A JP2025501731A (ja) | 2025-01-23 |
| JP2025501731A5 true JP2025501731A5 (cg-RX-API-DMAC10.html) | 2025-12-23 |
Family
ID=85157159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024536420A Pending JP2025501731A (ja) | 2021-12-20 | 2022-12-16 | イオン化可能なアミン脂質及び脂質ナノ粒子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240335385A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4452935A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025501731A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022418511A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3241488A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023121975A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7600208B2 (ja) | 2019-07-29 | 2024-12-16 | ジョージア テック リサーチ コーポレイション | 拘束された脂質を含むナノ材料およびその使用 |
| CN115175894B (zh) | 2020-01-09 | 2024-09-06 | 盖德治疗有限责任公司 | 纳米材料 |
| CN116761888A (zh) | 2021-01-20 | 2023-09-15 | 比姆医疗股份有限公司 | 纳米材料 |
| EP4281080A4 (en) | 2021-01-20 | 2025-09-24 | Beam Therapeutics Inc | NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT |
| WO2024078614A1 (zh) * | 2022-10-13 | 2024-04-18 | 深圳深信生物科技有限公司 | 用于递送生物活性成分的氨基脂质化合物和脂质纳米颗粒 |
| US20250381150A1 (en) | 2024-03-08 | 2025-12-18 | Genzyme Corporation | Lipid nanoparticles |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026030375A2 (en) | 2024-07-30 | 2026-02-05 | Genzyme Corporation | Lipid nanoparticles and methods of manufacture and use thereof |
| WO2026142951A1 (en) | 2024-12-23 | 2026-07-02 | Genzyme Corporation | Pharmaceutical system |
| US20260183424A1 (en) * | 2024-12-26 | 2026-07-02 | Eisai R&D Management Co., Ltd. | Ionizable lipids for nucleic acid delivery |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1021549A2 (en) | 1997-09-19 | 2000-07-26 | Sequitur, Inc. | SENSE mRNA THERAPY |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| EP4481047A3 (en) * | 2010-06-03 | 2025-04-16 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| DE21212055T1 (de) * | 2011-12-07 | 2022-08-04 | Alnylam Pharmaceuticals, Inc. | Biologisch abbaubare lipide zur freisetzung von wirkstoffen |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| US10426737B2 (en) * | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| HRP20220156T1 (hr) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| CN111542338B (zh) * | 2017-12-27 | 2024-06-18 | 武田药品工业株式会社 | 含核酸脂质纳米粒子及其用途 |
| EP3924479A4 (en) | 2019-02-13 | 2023-01-25 | Beam Therapeutics, Inc. | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE |
| WO2020219876A1 (en) * | 2019-04-25 | 2020-10-29 | Intellia Therapeutics, Inc. | Ionizable amine lipids and lipid nanoparticles |
| CA3143865A1 (en) * | 2019-06-07 | 2020-12-10 | Fujifilm Corporation | Lipid composition |
-
2022
- 2022-12-16 CA CA3241488A patent/CA3241488A1/en active Pending
- 2022-12-16 AU AU2022418511A patent/AU2022418511A1/en active Pending
- 2022-12-16 WO PCT/US2022/053209 patent/WO2023121975A1/en not_active Ceased
- 2022-12-16 EP EP22851198.6A patent/EP4452935A1/en active Pending
- 2022-12-16 JP JP2024536420A patent/JP2025501731A/ja active Pending
-
2024
- 2024-06-18 US US18/746,810 patent/US20240335385A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025500824A5 (cg-RX-API-DMAC10.html) | ||
| JP7654724B2 (ja) | 治療剤の細胞内送達のための化合物および組成物 | |
| JP2024505449A5 (cg-RX-API-DMAC10.html) | ||
| JP2024508347A5 (cg-RX-API-DMAC10.html) | ||
| JP2024503441A5 (cg-RX-API-DMAC10.html) | ||
| AU2019277361B2 (en) | Messenger RNA vaccines and uses thereof | |
| JP4491136B2 (ja) | 関節症を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤 | |
| TWI269652B (en) | Transnasal anticonvulsive compositions and modulated process | |
| JP2024502954A5 (cg-RX-API-DMAC10.html) | ||
| EA033966B1 (ru) | Стереохимически обогащенные композиции для доставки нуклеиновых кислот | |
| RU2126417C1 (ru) | Сложные эфиры нуклеозидов, фармацевтическая композиция | |
| JP2024503976A5 (cg-RX-API-DMAC10.html) | ||
| JP2009533457A (ja) | C−ニトロソから誘導されるニトロキシル供与体 | |
| JP2002538200A (ja) | 長鎖炭化水素およびヌクレオシド類似体によるウイルス複製の相乗的阻害 | |
| JP2002527522A (ja) | 慢性C型肝炎感染を有する患者における検出可能HCV−RNA根絶用リバビリン−インターフェロン−α併用療法 | |
| WO2025146125A1 (zh) | 用于递送的脂质化合物和脂质纳米颗粒 | |
| CN117430541B (zh) | 用于向细胞递送的化合物及其组合物 | |
| JP2025533111A (ja) | Rnaコンストラクト及びその使用 | |
| CN117899048A (zh) | 一种靶向脂质纳米粒及其制备与应用 | |
| WO2024078614A1 (zh) | 用于递送生物活性成分的氨基脂质化合物和脂质纳米颗粒 | |
| CN120754284B (zh) | 一种用于肝脏靶向联合递送CRISPR-Cas9系统和单链DNA修复模板的脂质纳米颗粒 | |
| KR20250164231A (ko) | 작용제의 전달을 위한 지질 나노입자 | |
| JP7842738B2 (ja) | バイオインスパイアード脂質誘導体及びその使用 | |
| KR20240167649A (ko) | 아미노 지질 화합물, 이의 제조 방법, 이의 조성물 및 이의 용도 | |
| CN100367948C (zh) | 三环-[5.2.1.02.6]-癸-9-基-黄原酸酯的纯立体异构体的制备和由其制成的药物 |